ev3 neurovascular




    President, Neurovascular Division, ev3 Inc.
    Smart Business, the management journal for corporate growth. Providing best practices and winning business strategies from the nation's most successful CEO and insight and ... ...
    http://www.sbnonline.com/Local/Article/13215/77/0/Matthew_Jenusaitis.a....
    of a platinum embolization
    Micro Therapeutics. Inc. DBA ev3 Neurovascular Traditional 510(k)/ FX Detachable Coil System 1/ 510(k) Summary Trade Name: FX Detachable Coil System Generic Name: Neurovascular ...
    http://www.fda.gov/cdrh/pdf6/K060747.pdf
    Summary
    fo46' Micro Therapeutics. Inc. DBA ev3 Neurovascular Special 510(k), Nexus Morpheus 3D CSR 510(k) Summary APP 2 P 7nr Trade Name: Nexus Morpheus 3D CSR Generic Name: Neurovascular ...
    http://www.fda.gov/cdrh/pdf6/K060625.pdf
    Summary of EV3 INC. - Yahoo! Finance
    On June 28, 2006, our operating subsidiaries, ev3 Endovascular, Inc., ev3 International, Inc. and ev3 Neurovascular, entered into a Loan and Security Agreement with Silicon Valley ...
    http://au.us.biz.yahoo.com/e/070314/evvv10-k.html
    ev3 Inc. Reports 2007 Fourth Quarter and Full-Year Financial Results ...
    In the fourth quarter of 2007, ev3's neurovascular segment net sales increased 20% to $28.3 million versus $23.7 million in the fourth quarter of 2006.
    http://au.us.biz.yahoo.com/prnews/080222/aqf013.html?.v=37
    ev3 Inc. Reports 2007 Fourth Quarter and Full-Year Financial Results ...
    In the fourth quarter of 2007, ev3's neurovascular segment net sales increased 20% to $28.3 million versus $23.7 million in the fourth quarter of 2006.
    http://www.reuters.com/article/pressRelease/idUS124623+22-Feb-2008+PRN....
    ev3 Inc. Announces Preliminary Fourth Quarter 2007 Net Sales Results ...
    In the fourth quarter of 2007, ev3's neurovascular segment net sales increased 20% to $28.3 million versus $23.7 million in the fourth quarter of 2006.
    http://www.reuters.com/article/pressRelease/idUS119926+07-Jan-2008+BW2....
    Ev3's Onyx HD 500 Receives HDE Approval From FDA For Treatment Of ...
    Onyx HD 500 will be marketed in the United States by the ev3 Neurovascular sales force. As the first liquid embolic to be approved for the treatment of cerebral aneurysms, the ...
    http://www.medicalnewstoday.com/articles/67973.php
    ev3 Inc. Announces Preliminary First Quarter 2008 Revenue - FoxHollow ...
    ... through the development of innovative endovascular therapies. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular ...
    http://investor.foxhollowtech.com/releasedetail.cfm?ReleaseID=304126
    FoxHollow Technologies, Inc. - Other
    ... platforms – SilverHawk and Rinspirator for FoxHollow; stents, balloons, and embolic filters for ev3 Cardio-Peripheral; and embolic coils and liquid embolics for ev3 Neurovascular ...
    http://investor.foxhollowtech.com/secfiling.cfm?filingID=1193125-07-21....